Apatinib is a novel selective VEGFR-2 inhibitor that inhibits the proliferative ability of thyroid carcinoma and squamous cell carcinoma in vivo and vitro and has been identified in multiple studies.281,282 In a tumor xenograft model, mice benefited from either apatinib alone or apatinib in combination with cytotoxic drugs.283 Tumor angiogenesis was also suppressed after apatinib treatment. Here, KDR is linked to neoplasm.